Zobrazeno 1 - 10
of 47
pro vyhledávání: '"63"'
Autor:
Frédéric Marchal, Jean-Marc Classe, Dominique Elias, Julia Bonastre, Julie Chevalier, Jean-Marc Guilloit, Diane Goéré, Antoine Brouquet, Gwenael Ferron, Jérémie H. Lefevre, Pierre Meeus
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (5), pp.681-685. ⟨10.1200/JCO.2008.19.7160⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (5), pp.681-685. ⟨10.1200/JCO.2008.19.7160⟩
Purpose To compare the long-term survival of patients with isolated and resectable peritoneal carcinomatosis (PC) in comparable groups of patients treated with systemic chemotherapy containing oxaliplatin or irinotecan or by cytoreductive surgery plu
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over
Autor:
Uwe M. Martens, Swen Wessendorf, Heinemann, Petra Buechner-Steudel, J. Greeve, Axel Florschütz, Thomas J. Ettrich, Andrea Tannapfel, Anke Reinacher-Schick, Thomas Seufferlein, Michael Geissler, Swantje Held, Jens Atzpodien, Jens Ricke, Max Seidensticker, Jorge Riera-Knorrenschild, Stephan Kanzler, Dominik Paul Modest, Dominik Nörenberg
Publikováno v:
Journal of Clinical Oncology. 37:3401-3411
PURPOSE This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreated
Autor:
Giovanni Begossi, S. R. Sanikommu, Charu Taneja, Harold J. Wanebo, Frank J. Cummings, James F. Belliveau
Publikováno v:
Journal of Clinical Oncology. 29:e14151-e14151
e14151 Background: Previously treated hepatic colorectal metastases (CRC) and advanced hepato cellular cancer (HCC) are tumor challenges frequently unresponsive to systemic chemo therapy (CT). We reviewed survival outcome in chemo-resistant/high-risk
Autor:
Xiao-Mei Li, Mohamed Bouchahda, Pasquale F. Innominato, F. Kunstlinger, Sylvie Giacchetti, D. Hauteville, Francis Lévi, René Adam, Denis Castaing, David Machover
Publikováno v:
Journal of Clinical Oncology. 25:14554-14554
14554 Background: Chronomodulated (Chrono) irinotecan (I), 5-fluorouracil (F), leucovorin and oxaliplatin (O) offered sustained tumor control in CRC patients (pts) failing several chemo (Gholam et al. The Oncologist 2006). The relevance of Chrono IFO
Autor:
Mohamed Hebbar, J. R. Mel Lorenzo, B. Landi, Arie Figer, T. Andre, Gérard Lledo, Christophe Tournigand, Emmanuel Achille, M. Flesch, Isabel Chirivella
Publikováno v:
Journal of Clinical Oncology. 22:3565-3565
3565 Background: High alkaline phosphatases (Alk Ph) level is an adverse prognostic factor in patients (pts) with metastatic colo-rectal cancer (CRC). Pts with Alk Ph level over 3-time the upper normal value (UNV) were excluded from previous studies.
Autor:
Arie Figer, E. Quinaux, T. Andre, Gérard Lledo, A. de Gramont, G. Russ, L. Mineur, A. Cervantes, P.L. Etienne, M. Flesch
Publikováno v:
Journal of Clinical Oncology. 22:3525-3525
3525 Background: FOLFOX4 has shown superiority over LV5FU2 and IFL in first line therapy. Limiting toxicities are neutropenia mainly due to 5FU bolus and cumulative sensory neurotoxicity which imposes to stop oxaliplatin (ox). OPTIMOX is a phase III
Autor:
Jing Gao, Meng Wei, Fei Xie, Wei-Wei Lv, Lian Liu, Song Li, Wenbin Yu, Lei Sheng, Jiaqian Wang, Zhimin Liu, Zhikun Zhao, Cheng Chen, Dexin Yu, Yongtian Zhao, Duanbo Shi
Publikováno v:
Journal of Clinical Oncology. 39:4061-4061
4061 Background: The prognosis of cT4a/bN+ gastric cancer (GC) is poor due to low R0 resection rate and frequent recurrence. We evaluated the feasibility, safety, and efficacy of a combination of immunotherapy, anti-angiogenesis, and chemotherapy for
Autor:
Kotoe Oshima, Atsuo Takashima, Satoru Iwasa, Hidekazu Hirano, Narikazu Boku, Yoshitaka Honma, Toshiharu Hirose, Koshiro Ishiyama, Ken Kato, Hiroyuki Daiko, Natsuko Okita Tsuda, Hirokazu Shoji, Shun Yamamoto, Zyunya Oguma
Publikováno v:
Journal of Clinical Oncology. 39:209-209
209 Background: In Western countries, 5-FU plus leucovorin, oxaliplatin, docetaxel (DTX) (FLOT) is the standard perioperative treatment for resectable gastric adenocarcinoma and esophagogastric junction adenocarcinoma (EGJ-AC). Preoperative chemother
Autor:
Andrea Spallanzani, Filippo Giovanardi, Elisa Giommoni, Francesco Iachetta, Antonia Strippoli, Maria Antonietta Satolli, Michele Sisani, Daniele Lavacchi, Francesca Salani, Samantha Di Donato, Luca Pompella, Lorenzo Antonuzzo, Vincenzo Formica, Michele Prisciandaro, Goirc, Floriana Nappo, Irene Pecora, Giuseppe Tirino, Carmelo Pozzo, Marco Puzzoni, Ferdinando De Vita
Publikováno v:
Journal of Clinical Oncology. 38:4548-4548
4548 Background: The treatment strategy for patients with resectable gastric cancer changed in the last few years with perioperative treatments. FLOT regimen (fluorouracil, oxaliplatin, docetaxel) turned out to be feasible and effective, offering sig